Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETOPROFEN vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Mild to moderate pain,Dysmenorrhea,Acute gouty arthritis (off-label)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Hepatic metabolism via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C9; conjugation with glucuronic acid; minor hydrolysis to metabolites.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
99% bound, primarily to albumin; free fraction increases in hypoalbuminemia.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.1-0.2 L/kg; clinical meaning: low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid; higher in elderly due to increased body fat.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: ~90% (capsules); Topical: 5-10% (systemic absorption); Rectal: ~80%; Intramuscular: ~100%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl >50 m L/min: no adjustment. Cr Cl 25-50 m L/min: reduce dose to 50% of normal. Cr Cl <25 m L/min: avoid use or maximum 50 mg twice daily.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Children ≥6 months: oral 1-2 mg/kg/day divided every 6-8 hours; maximum 4 mg/kg/day. Not to exceed adult maximum.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at lowest effective dose (e.g., 50 mg twice daily); use short duration; monitor renal function, GI bleeding, and cardiovascular risk.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; hepatic toxicity; use with caution in patients with asthma or history of GI bleeding.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
History of hypersensitivity to ketoprofen, aspirin, or other NSAIDs; active peptic ulcer disease; history of gastrointestinal bleeding or perforation; severe renal impairment; severe hepatic impairment; during perioperative pain in CABG surgery.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid alcohol as it increases the risk of GI bleeding. Taking with food may reduce gastrointestinal irritation but delays absorption.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohydramnios, constriction of ductus arteriosus. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, fetal nephrotoxicity, and periventricular hemorrhage.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Compatible with caution. Small amounts excreted in breast milk (M/P ratio ~0.01-0.1). Due to risk of infant toxicity (e.g., gastrointestinal effects, renal impairment), consider alternative analgesics. Monitor infant for drowsiness, poor feeding, or rash.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustments recommended; use lowest effective dose for shortest duration. Increased clearance in pregnancy may necessitate dose adjustment, but avoid in third trimester. Use with caution in first and second trimesters due to maternal volume expansion and increased renal clearance.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Maximum analgesic effect occurs at 50 mg oral doses; higher doses increase GI toxicity without additional pain relief. Use with caution in patients with renal impairment as ketoprofen decreases renal blood flow. Avoid use with other NSAIDs, including aspirin, due to increased ulcer risk. Ketoprofen is highly protein-bound; monitor for displacement interactions with warfarin and oral hypoglycemics.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; taking more does not provide extra pain relief.,Avoid alcohol while taking this medication.,Contact your doctor immediately if you experience black or bloody stools, chest pain, or signs of an allergic reaction.,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"The concurrent use of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), with gemeprost, a synthetic prostaglandin E1 analogue used for cervical ripening and induction of labor, may antagonize the therapeutic effects of gemeprost. Ketoprofen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which directly opposes the prostaglandin-mediated actions of gemeprost, such as cervical softening and uterine contraction. This pharmacodynamic antagonism can lead to decreased efficacy of gemeprost in achieving cervical ripening or inducing labor, potentially prolonging the induction-to-delivery interval or necessitating alternative interventions."
"Amodiaquine inhibits CYP2C9, the primary enzyme responsible for metabolizing ketoprofen. This results in decreased clearance and elevated plasma concentrations of ketoprofen, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may experience heightened analgesic and anti-inflammatory effects, but also a greater propensity for NSAID-related toxicity."
"Lumacaftor, a strong cytochrome P450 (CYP) 3A4 inducer, significantly decreases the systemic exposure of ketoprofen, a CYP3A4 substrate, by increasing its hepatic metabolism. This interaction can lead to reduced ketoprofen plasma concentrations, potentially compromising its analgesic and anti-inflammatory efficacy. Clinically, patients may experience suboptimal pain relief or require alternative pain management strategies."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETOPROFEN vs ALFENTA, answered by our medical review team.
KETOPROFEN is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETOPROFEN and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETOPROFEN is: Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETOPROFEN and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETOPROFEN is classified as Category D/X. First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohy. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.